{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T12:29:59Z","timestamp":1776947399297,"version":"3.51.4"},"reference-count":102,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T00:00:00Z","timestamp":1755388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Currently, it is routine to determine the treatment plans for pancreatic ductal adenocarcinoma (PDAC) based on the resectability status, which is classified into: resectable (R), borderline resectable (BR), and unresectable (UR). In patients with R-PDAC, we have frequently encountered distant metastases only after laparotomy. In addition, early postoperative recurrence may be noted even after curative resection. To overcome these issues, preoperative treatment has been recommended to estimate the tumor aggressiveness and avoid unnecessary surgery. For BR disease, all clinical trials comparing upfront surgery with preoperative treatment have shown a better prognosis with the latter. For UR disease, especially with distant metastases, a previous multi-institutional retrospective study suggested that we should consider conversion surgery after at least 8\u00a0months of chemotherapy. However, the postoperative prognosis remains unsatisfactory. Appropriate regimens and durations of preoperative treatment for each respectability status have yet to be established. Other issues, such as the feasibility of arterial reconstruction and whether all metastatic lesions should be removed, remain to be addressed.<\/jats:p>","DOI":"10.1093\/jjco\/hyaf131","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T11:22:29Z","timestamp":1754306549000},"page":"1306-1315","source":"Crossref","is-referenced-by-count":2,"title":["Surgery based on resectability status of pancreatic cancer: a narrative review"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4434-0803","authenticated-orcid":false,"given":"Takahiro","family":"Einama","sequence":"first","affiliation":[{"name":"Department of Surgery, National Defense Medical College , 3-2 Namiki, Tokorozawa, Saitama 359-8513 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuko","family":"Ohara","sequence":"additional","affiliation":[{"name":"Department of Surgery, National Defense Medical College , 3-2 Namiki, Tokorozawa, Saitama 359-8513 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Ichio","sequence":"additional","affiliation":[{"name":"Department of Surgery, National Defense Medical College , 3-2 Namiki, Tokorozawa, Saitama 359-8513 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Surgery, National Defense Medical College , 3-2 Namiki, Tokorozawa, Saitama 359-8513 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanae","family":"Shinada","sequence":"additional","affiliation":[{"name":"Department of Surgery, National Defense Medical College , 3-2 Namiki, Tokorozawa, Saitama 359-8513 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Yonamine","sequence":"additional","affiliation":[{"name":"Department of Surgery, National Defense Medical College , 3-2 Namiki, Tokorozawa, Saitama 359-8513 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takazumi","family":"Tsunenari","sequence":"additional","affiliation":[{"name":"Department of Surgery, National Defense Medical College , 3-2 Namiki, Tokorozawa, Saitama 359-8513 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikiya","family":"Takao","sequence":"additional","affiliation":[{"name":"Department of Surgery, National Defense Medical College , 3-2 Namiki, Tokorozawa, Saitama 359-8513 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Takihata","sequence":"additional","affiliation":[{"name":"Department of Surgery, National Defense Medical College , 3-2 Namiki, Tokorozawa, Saitama 359-8513 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8600-1199","authenticated-orcid":false,"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Surgery, National Defense Medical College , 3-2 Namiki, Tokorozawa, Saitama 359-8513 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8885-1210","authenticated-orcid":false,"given":"Yoji","family":"Kishi","sequence":"additional","affiliation":[{"name":"Department of Surgery, National Defense Medical College , 3-2 Namiki, Tokorozawa, Saitama 359-8513 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,17]]},"reference":[{"key":"2025120323365340300_ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041101","article-title":"Prognosis of pancreatic cancer based on Resectability: a single Center experience","volume":"15","author":"Einama","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025120323365340300_ref2","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.6004\/jnccn.2017.0131","article-title":"Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Tempero","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"2025120323365340300_ref3","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.pan.2023.06.005","article-title":"\u201cConversion surgery\u201d for locally advanced pancreatic cancer: a position paper by the study group at the joint meeting of the International Association of Pancreatology (IAP) & Japan pancreas society (JPS) 2022","volume":"23","author":"Oba","year":"2023","journal-title":"Pancreatology"},{"key":"2025120323365340300_ref4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/jhbp.1437","article-title":"Conversion surgery for initially unresectable locally advanced biliary tract cancer: a multicenter collaborative study conducted in Japan and Korea","volume":"31","author":"Yabushita","year":"2024","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025120323365340300_ref5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/jhbp.12066","article-title":"Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: a multicenter retrospective cohort study (PC-CURE-1)","volume":"31","author":"Okano","year":"2024","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025120323365340300_ref6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/00006676-200404000-00002","article-title":"Pancreatic cancer registry in Japan: 20 years of experience","volume":"28","author":"Matsuno","year":"2004","journal-title":"Pancreas"},{"key":"2025120323365340300_ref7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"2025120323365340300_ref8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"2025120323365340300_ref9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"2025120323365340300_ref10","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"2025120323365340300_ref11","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1200\/JCO.22.01134","article-title":"Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label","volume":"41","author":"Tempero","year":"2023","journal-title":"Phase III Trial J Clin Oncol"},{"key":"2025120323365340300_ref12","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for Resectable and borderline Resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025120323365340300_ref13","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/jhbp.1353","article-title":"Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04)","volume":"30","author":"Sugiura","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025120323365340300_ref14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12885-021-08031-z","article-title":"Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial","volume":"21","author":"Janssen","year":"2021","journal-title":"BMC Cancer"},{"key":"2025120323365340300_ref15","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1245\/s10434-011-2110-8","article-title":"Neoadjuvant\/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies","volume":"19","author":"Andriulli","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"2025120323365340300_ref16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12032-017-0951-0","article-title":"Neoadjuvant treatment in pancreatic cancer: evidence-based medicine? A systematic review and meta-analysis","volume":"34","author":"D'Angelo","year":"2017","journal-title":"Med Oncol"},{"key":"2025120323365340300_ref17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s00535-018-1506-7","article-title":"A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study","volume":"54","author":"Motoi","year":"2019","journal-title":"J Gastroenterol"},{"key":"2025120323365340300_ref18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/jjco\/hyy190","article-title":"Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP05)","volume":"49","author":"Motoi","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"2025120323365340300_ref19","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006730","article-title":"Neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for Resectable pancreatic cancer: results of the randomized phase II\/III Prep-02\/JSAP05 trial","author":"Unno","year":"2025","journal-title":"Ann Surg"},{"key":"2025120323365340300_ref20","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO-24-01378","article-title":"Neoadjuvant FOLF(IRIN)OX chemotherapy for Resectable pancreatic adenocarcinoma: a Multicenter randomized noncomparative phase II trial (PANACHE01 FRENCH08 PRODIGE48 study)","volume":"43","author":"Schwarz","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025120323365340300_ref21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025120323365340300_ref22","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1245\/s10434-024-15199-8","article-title":"Results of a randomized clinical study of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for Resectable and borderline Resectable pancreatic ductal adenocarcinoma (RCT, CSGO-HBP-015)","volume":"31","author":"Yamada","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2025120323365340300_ref23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","article-title":"Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group","volume":"34","author":"Seufferlein","year":"2023","journal-title":"Ann Oncol"},{"key":"2025120323365340300_ref24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of perioperative chemotherapy for Resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025120323365340300_ref25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/MPA.0000000000001579","article-title":"Optimal treatment for octogenarians with Resectable and borderline Resectable pancreatic ductal adenocarcinoma: a Multicenter retrospective study","volume":"49","author":"Satoi","year":"2020","journal-title":"Pancreas"},{"key":"2025120323365340300_ref26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijsu.2016.02.064","article-title":"Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head is justified in elderly patients: a retrospective cohort study","volume":"28","author":"Renz","year":"2016","journal-title":"Int J Surg"},{"key":"2025120323365340300_ref27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jamcollsurg.2007.06.307","article-title":"Outcomes in octogenarians undergoing high-risk cancer operation: a national study","volume":"205","author":"Finlayson","year":"2007","journal-title":"J Am Coll Surg"},{"key":"2025120323365340300_ref28","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1007\/s11605-021-04949-8","article-title":"Mortality and survival among octogenarians with localized pancreatic head cancer: a National Cancer Database Analysis","volume":"25","author":"Hue","year":"2021","journal-title":"J Gastrointest Surg"},{"key":"2025120323365340300_ref29","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1007\/s11605-010-1294-8","article-title":"Pancreatoduodenectomy for ductal adenocarcinoma in the very elderly; is it safe and justified?","volume":"14","author":"Khan","year":"2010","journal-title":"J Gastrointest Surg"},{"key":"2025120323365340300_ref30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejso.2012.08.017","article-title":"Pancreatectomy for adenocarcinoma in elderly patients: postoperative outcomes and long term results: a study of the French surgical association","volume":"39","author":"Turrini","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"2025120323365340300_ref31","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1477-2574.2012.00484.x","article-title":"The safety of a pancreaticoduodenectomy in patients older than 80 years: risk vs. benefits","volume":"14","author":"Melis","year":"2012","journal-title":"HPB (Oxford)"},{"key":"2025120323365340300_ref32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/jhbp.687","article-title":"Reappraisal of the validity of surgery for patients with pancreatic cancer aged 80 years or older stratified by resectability status","volume":"27","author":"Kondo","year":"2020","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025120323365340300_ref33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","article-title":"Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and bowel project B-18","volume":"30","author":"Wolmark","year":"2001","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2025120323365340300_ref34","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1186\/s12885-023-11141-5","article-title":"Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial","volume":"23","author":"Dam","year":"2023","journal-title":"BMC Cancer"},{"key":"2025120323365340300_ref35","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1245\/s10434-024-15817-5","article-title":"ALLIANCE A021806: a phase III trial of perioperative versus adjuvant chemotherapy for Resectable pancreatic cancer","volume":"31","author":"Eade","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2025120323365340300_ref36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"2025120323365340300_ref37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153688","article-title":"Clinical impact of dual time point (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography fusion imaging in pancreatic cancer","volume":"14","author":"Einama","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025120323365340300_ref38","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/jhbp.1049","article-title":"New criteria of resectability for pancreatic cancer: a position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS)","volume":"29","author":"Oba","year":"2022","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025120323365340300_ref39","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/jhbp.12056","article-title":"Japanese classification of pancreatic carcinoma by the Japan pancreas society: eighth edition","volume":"31","author":"Ishida","year":"2024","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025120323365340300_ref40","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1007\/s00268-015-3096-3","article-title":"National Comprehensive Cancer Network Resectability Status for pancreatic carcinoma predicts overall survival","volume":"39","author":"Murakami","year":"2015","journal-title":"World J Surg"},{"key":"2025120323365340300_ref41","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00534-013-0595-1","article-title":"Clinical features and treatment outcome of borderline resectable pancreatic head\/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery","volume":"20","author":"Kato","year":"2013","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025120323365340300_ref42","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1097\/MD.0000000000001647","article-title":"Inverse probability of treatment weighting analysis of upfront surgery versus neoadjuvant chemoradiotherapy followed by surgery for pancreatic adenocarcinoma with arterial abutment","volume":"94","author":"Fujii","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2025120323365340300_ref43","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1097\/MPA.0000000000000634","article-title":"Treatment strategy for borderline Resectable pancreatic cancer with radiographic artery involvement","volume":"45","author":"Hirono","year":"2016","journal-title":"Pancreas"},{"key":"2025120323365340300_ref44","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00280-017-3281-1","article-title":"Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact","volume":"79","author":"Murakami","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025120323365340300_ref45","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.suronc.2017.08.003","article-title":"A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma","volume":"26","author":"Ielpo","year":"2017","journal-title":"Surg Oncol"},{"key":"2025120323365340300_ref46","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/SLA.0000000000002600","article-title":"Predictors of Resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX","volume":"269","author":"Michelakos","year":"2019","journal-title":"Ann Surg"},{"key":"2025120323365340300_ref47","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1245\/s10434-018-07131-8","article-title":"Clinical impact of neoadjuvant chemotherapy and chemoradiotherapy in borderline Resectable pancreatic cancer: analysis of 884 patients at facilities specializing in pancreatic surgery","volume":"26","author":"Nagakawa","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"2025120323365340300_ref48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/jhbp.844","article-title":"Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: intention-to-treat analysis compared with upfront surgery","volume":"28","author":"Inoue","year":"2021","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025120323365340300_ref49","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline Resectable pancreatic cancer: a prospective, randomized, open-label, Multicenter phase 2\/3 trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"key":"2025120323365340300_ref50","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1097\/SLA.0000000000004535","article-title":"Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline Resectable pancreatic cancer: a phase II open-label Multicenter prospective trial (JASPAC05)","volume":"276","author":"Takahashi","year":"2022","journal-title":"Ann Surg"},{"key":"2025120323365340300_ref51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejca.2021.10.012","article-title":"A phase II study of gemcitabine\/nab-paclitaxel\/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact","volume":"159","author":"Kondo","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025120323365340300_ref52","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/SLA.0000000000005430","article-title":"Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM\/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01)","volume":"275","author":"Yamaguchi","year":"2022","journal-title":"Ann Surg"},{"key":"2025120323365340300_ref53","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus Hypofractionated radiotherapy for borderline Resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025120323365340300_ref54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025120323365340300_ref55","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/ags3.12712","article-title":"Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: a multicenter single-arm phase II study (NAC-GA trial)","volume":"7","author":"Okada","year":"2023","journal-title":"Ann Gastroenterol Surg"},{"key":"2025120323365340300_ref56","doi-asserted-by":"publisher","first-page":"LBA4014","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4014","article-title":"Randomized phase II\/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study","volume":"42","author":"Ikeda","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025120323365340300_ref57","doi-asserted-by":"publisher","first-page":"S1252","DOI":"10.1016\/j.annonc.2024.08.2304","article-title":"LBA62 preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the randomized phase II trial PANDAS\/PRODIGE 44","volume":"35","author":"Lambert","year":"2024","journal-title":"Ann Oncol"},{"key":"2025120323365340300_ref58","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/jhbp.748","article-title":"Tumor marker recovery rather than major pathological response is a preferable prognostic factor in patients with pancreatic ductal adenocarcinoma with preoperative therapy","volume":"27","author":"Yamada","year":"2020","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025120323365340300_ref59","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/SLA.0000000000005184","article-title":"Prognosis associated with CA19-9 response dynamics and normalization during neoadjuvant therapy in resected pancreatic adenocarcinoma","volume":"277","author":"Newhook","year":"2023","journal-title":"Ann Surg"},{"key":"2025120323365340300_ref60","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.pan.2023.10.014","article-title":"Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic ductal adenocarcinoma","volume":"23","author":"Terai","year":"2023","journal-title":"Pancreatology"},{"key":"2025120323365340300_ref61","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/jhbp.258","article-title":"Importance of resectability status in neoadjuvant treatment for pancreatic cancer","volume":"22","author":"Sho","year":"2015","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025120323365340300_ref62","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025120323365340300_ref63","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1245\/s10434-020-09149-3","article-title":"Total neoadjuvant therapy for operable pancreatic cancer","volume":"28","author":"Kim","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"2025120323365340300_ref64","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/SLA.0000000000003284","article-title":"Factors predicting response, perioperative outcomes, and survival following Total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer","volume":"273","author":"Truty","year":"2021","journal-title":"Ann Surg"},{"key":"2025120323365340300_ref65","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/ags3.12726","article-title":"Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement","volume":"8","author":"Akahori","year":"2024","journal-title":"Ann Gastroenterol Surg"},{"key":"2025120323365340300_ref66","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s00534-013-0616-0","article-title":"Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery","volume":"20","author":"Satoi","year":"2013","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025120323365340300_ref67","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"2025120323365340300_ref68","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"2025120323365340300_ref69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184733","article-title":"The survival benefit of chemoradiotherapy following induction chemotherapy with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer","volume":"13","author":"Takada","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025120323365340300_ref70","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/ags3.12613","article-title":"Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: results of a dual-center study","volume":"7","author":"Igarashi","year":"2023","journal-title":"Ann Gastroenterol Surg"},{"key":"2025120323365340300_ref71","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","article-title":"Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial","volume":"6","author":"Kunzmann","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025120323365340300_ref72","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/SLA.0000000000005666","article-title":"Early recurrence after resection of locally advanced pancreatic cancer following induction therapy: an international Multicenter study","volume":"278","author":"Seelen","year":"2023","journal-title":"Ann Surg"},{"key":"2025120323365340300_ref73","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.pan.2023.06.001","article-title":"Significance of multiple tumor markers measurements in conversion surgery for unresectable locally advanced pancreatic cancer","volume":"23","author":"Nagai","year":"2023","journal-title":"Pancreatology"},{"key":"2025120323365340300_ref74","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/01.sla.0000258608.52615.5a","article-title":"Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: Long-term results","volume":"246","author":"Hirano","year":"2007","journal-title":"Ann Surg"},{"key":"2025120323365340300_ref75","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1245\/s10434-016-5493-8","article-title":"Distal pancreatectomy with en bloc celiac Axis resection (modified Appleby procedure) for locally advanced pancreatic body cancer: a single-Center review of 80 consecutive patients","volume":"23","author":"Nakamura","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2025120323365340300_ref76","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s13304-020-00826-2","article-title":"Distal pancreatectomy with en bloc celiac axis resection for pancreatic cancer: a pooled analysis of 109 cases","volume":"72","author":"Lan","year":"2020","journal-title":"Updat Surg"},{"key":"2025120323365340300_ref77","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00423-019-01775-0","article-title":"Feasibility and safety of distal pancreatectomy with en bloc celiac axis resection (DP-CAR) combined with neoadjuvant therapy for borderline resectable and unresectable pancreatic body\/tail cancer","volume":"404","author":"Yoshitomi","year":"2019","journal-title":"Langenbeck's Arch Surg"},{"key":"2025120323365340300_ref78","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.hpb.2017.02.437","article-title":"Superior mesenteric artery (SMA) resection during pancreatectomy for malignant disease of the pancreas: a systematic review","volume":"19","author":"Jegatheeswaran","year":"2017","journal-title":"HPB (Oxford)"},{"key":"2025120323365340300_ref79","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00423-017-1578-5","article-title":"Combined hepatic arterial resection in pancreatic resections for locally advanced pancreatic cancer","volume":"402","author":"Miyazaki","year":"2017","journal-title":"Langenbeck's Arch Surg"},{"key":"2025120323365340300_ref80","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/jhbp.565","article-title":"Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment","volume":"25","author":"Asano","year":"2018","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025120323365340300_ref81","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1097\/SLA.0000000000003010","article-title":"Pancreatectomy with arterial resection for pancreatic adenocarcinoma: how can it Be done safely and with which outcomes?: a single Institution\u2019s experience with 118 patients","volume":"271","author":"Bachellier","year":"2020","journal-title":"Ann Surg"},{"key":"2025120323365340300_ref82","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1245\/s10434-022-11503-6","article-title":"Optimizing indications for conversion surgery based on analysis of 454 consecutive Japanese cases with unresectable pancreatic cancer who received modified FOLFIRINOX or gemcitabine plus nab-paclitaxel: a single-Center retrospective study","volume":"29","author":"Ushida","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2025120323365340300_ref83","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/SLA.0000000000004054","article-title":"Arterial resection in pancreatic cancer surgery: effective after a learning curve","volume":"275","author":"Loos","year":"2022","journal-title":"Ann Surg"},{"key":"2025120323365340300_ref84","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.surg.2021.12.029","article-title":"Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: an analysis of the National Cancer Database","volume":"171","author":"Hamad","year":"2022","journal-title":"Surgery"},{"key":"2025120323365340300_ref85","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jhbp.1184","article-title":"Outcomes of pancreatic cancer with liver oligometastasis","volume":"30","author":"Takeda","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025120323365340300_ref86","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1007\/s10147-021-01961-5","article-title":"Surgical margin clearance and extended chemotherapy defines survival for synchronous oligometastatic liver lesions of the ductal adenocarcinoma of the pancreas","volume":"26","author":"Safi","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"2025120323365340300_ref87","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3109\/07357907.2015.1080831","article-title":"Resection of late pulmonary metastases from pancreatic adenocarcinoma: is surgery an option?","volume":"33","author":"Brieau","year":"2015","journal-title":"Cancer Investig"},{"key":"2025120323365340300_ref88","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jso.23943","article-title":"The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas","volume":"112","author":"Downs-Canner","year":"2015","journal-title":"J Surg Oncol"},{"key":"2025120323365340300_ref89","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/jhbp.1127","article-title":"Outcomes of lung metastasis from pancreatic cancer: a nationwide multicenter analysis","volume":"29","author":"Homma","year":"2022","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025120323365340300_ref90","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.suronc.2019.08.010","article-title":"Oligometastatic pulmonary metastasis in pancreatic cancer patients: safety and outcome of resection","volume":"31","author":"Ilmer","year":"2019","journal-title":"Surg Oncol"},{"key":"2025120323365340300_ref91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051354","article-title":"Intraperitoneal paclitaxel treatment for patients with pancreatic ductal adenocarcinoma with peritoneal dissemination provides a survival benefit","volume":"14","author":"Yamamoto","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025120323365340300_ref92","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13063-022-06049-7","article-title":"Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)","volume":"23","author":"Yamamoto","year":"2022","journal-title":"Trials"},{"key":"2025120323365340300_ref93","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ijrobp.2015.12.362","article-title":"Carbon ion radiation therapy with concurrent gemcitabine for patients with locally advanced pancreatic cancer","volume":"95","author":"Shinoto","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025120323365340300_ref94","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.ijrobp.2018.04.057","article-title":"Multi-institutional study of carbon-ion radiotherapy for locally advanced pancreatic cancer: Japan carbon-ion radiation oncology study group (J-CROS) study 1403 pancreas","volume":"101","author":"Kawashiro","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025120323365340300_ref95","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.radonc.2018.08.026","article-title":"A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer","volume":"129","author":"Shinoto","year":"2018","journal-title":"Radiother Oncol"},{"key":"2025120323365340300_ref96","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"2025120323365340300_ref97","doi-asserted-by":"publisher","first-page":"1402128","DOI":"10.3389\/fonc.2024.1402128","article-title":"Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment","volume":"14","author":"Long","year":"2024","journal-title":"Front Oncol"},{"key":"2025120323365340300_ref98","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"2025120323365340300_ref99","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"2025120323365340300_ref100","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies\u2014improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015","volume":"26","author":"Coates","year":"2015","journal-title":"Ann Oncol"},{"key":"2025120323365340300_ref101","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"2025120323365340300_ref102","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/12\/1306\/64068825\/hyaf131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/12\/1306\/64068825\/hyaf131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T04:37:11Z","timestamp":1764823031000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/12\/1306\/8236562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,17]]},"references-count":102,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,8,17]]},"published-print":{"date-parts":[[2025,12,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf131","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,8,17]]}}}